Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial for the Treatment of Older Patients With Newly Diagnosed CD19 Positive, Ph/BCR-ABL Negative B-precursor Acute Lymphoblastic Leukemia With Sequential Dose Reduced Chemotherapy and Blinatumomab (EWALL-BOLD)

NCT03480438 is registered in ClinicalTrials.gov with Goethe University as lead sponsor.

NCT NCT03480438
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03480438 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial for the Treatment of Older Patients With Newly Diagnosed CD19 Positive, Ph/BCR-ABL Negative B-precursor Acute Lymphoblastic Leukemia With Sequential Dose Reduced Chemotherapy and Blinatumomab (EWALL-BOLD)
Lead sponsor
Goethe University
Phase
Phase 2
Overall status
Completed
Start date
June 1, 2018
Completion date
January 10, 2024
Enrollment
52 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

b-precursor all